Prostate Journal Articles and Videos
Radium-223 from Bench to Bedside – Future Directions for Targeted Alpha Therapy
European Oncology & Haematology. 2018;14(Suppl 2):3–9
Radiopharmaceuticals for the Detection of Recurrent Prostate Cancer
European Oncology & Haematology. 2018;14(1):16–17 DOI: https://doi.org/10.17925/EOH.2018.14.1.16
Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour
European Oncology & Haematology, 2018;14(1):12–13 DOI: https://doi.org/10.17925/EOH.2018.14.1.12
Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against
European Oncology & Haematology. 2018;14(1):14–15 DOI: https://doi.org/10.17925/EOH.2018.14.1.14
Judd W. Moul
Professor of Surgery, Director, Duke Prostate Center
In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Dr. Judd Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients. Dr. Moul has received grants from the National Institutes of Health, U.S. Department of Defense, Veterans Affairs and CaPCURE Foundation, and managed a cumulative $50 million in grants from the U.S. Army Medical Research and Materiel Command for the Department of Defense Center for Prostate Disease Research.
Dr. Moul serves on the editorial boards of Prostate Cancer, BJU International, American Journal of Men’s Health, Urology and World Journal of Urology, and has been Co-Editor of Prostate Cancer and Prostatic Diseases. He has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award for national involvement in prostate cancer patient support groups, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the prestigious Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General at the US Army, and the Castle Connolly National Physician of the Year award.
Associate Professor, Department of Urologic Sciences, University of British Columbia.
Dr. Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and an Associate Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and fellowship in urologic oncology at M.D. Anderson Cancer Center in Houston, Texas.
Dr. Black has a clinical sub-specialty interest in bladder and prostate cancer. His grant-funded translational research program focuses primarily on molecular biomarkers and targeted therapies in urothelial carcinoma. His recent work has identified genomic signatures that predict outcome after neoadjuvant chemotherapy in muscle-invasive bladder cancer, and these have recently been commercialized. He is an active clinical trialist and is currently principle investigator of a co-operative group (SWOG) trial testing atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.
Video List based on Category on Node Page
The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology: